BRISBANE, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that data on its molecular diagnostic surveillance solution AlloMap® and cell-free DNA (cfDNA) will be presented by several leading transplant clinicians at the 2015 American Transplant Congress (ATC) being held May 2-6 in Philadelphia, PA.
Saturday, May 2, 3:20 – 5:20 pm ET: Immune Monitoring in Thoracic Organ Transplantation: Clinical Applications
Dr. Michael Pham, MD, Stanford University
The Future is Now in Immune Monitoring after Heart Transplantation: The Clinical Use of Cell-Free DNA and mRNA
Monday, May 4, 8:30 – 9:30 am ET: Plenary Session II
Dr. Jon Kobashigawa, MD, Cedars- Sinai Medical Center
Plasma Levels of Donor-Derived Cell-Free DNA Increase With Rejection and Often Decrease After Treatment in Organ Transplant Recipients
Monday, May 4, 2:15 – 3:45 pm ET: Heart De-"Mystification": Rejection and Antibodies of All Types
Dr. Howard Eisen, MD, Hahnemann Hospital
Donor-Derived Cell-Free DNA Is Stable in Non-Rejecting Heart Transplant
Recipients in the CARGO II Multicenter Trial
Tuesday, May 5, 11:15 am – 12:45 pm ET: Midday Symposia: New Developments in Solid Organ Transplant Biomarkers
Dr. Kiran Khush, MD, Stanford University
Cell-Free DNA as a Diagnostic Marker for Transplant Rejection
"We are delighted by the growing body of evidence and support from key opinion leaders in the field of organ transplant surrounding our surveillance portfolio. We are all encouraged by the promise that rejection status in patient management may be further enhanced when information from cell-free DNA is added to AlloMap results," said Dr. Peter Maag, PhD, Chief Executive Officer of CareDx. "Continuing the excitement we generated with our multiple presentations on cell-free DNA and AlloMap a few weeks ago at the ISHLT conference in Nice, France, we are pleased to present these exciting findings to one of the largest forums in the U.S. for surgeons and clinicians in the field of solid organ and tissue transplantation."
In addition, the following scientific posters will be presented:
Tuesday, May 5, 5:30 – 6:30 pm ET: Exhibit Hall E
Poster #677: Clinical Use of Gene-Expression Profiling to Monitor for Rejection After Cardiac Transplantation – Which Patients and When?
Poster #681: Correlation of Longitudinal Gene-Expression Profiling (GEP) Score to Cytomegalovirus (CMV) Infection: Results From the Outcomes AlloMap Registry (OAR)
Poster #688: Can Gene-Expression Profiling Score Help Explain the Adverse Clinical Outcomes Seen in Gender-Mismatched Heart Transplants?
AlloMap Molecular Testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment. AlloMap is performed in the CLIA-certified and CAP-accredited clinical laboratory at CareDx and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Recommended use of AlloMap for heart transplant rejection surveillance is included in the International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the care of heart transplant recipients, published in August, 2010. These guidelines represent the worldwide standard for the care of heart transplant patients.
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. The Company is currently investigating a research use only donor-derived cell-free DNA-based test for heart transplant recipients. For more information, please visit: www.CareDx.com.
Forward Looking Statements
In addition to the historical information, this press release contains forward-looking statements including, but not limited to statements regarding the Company's expectations regarding future research, development and commercial activities. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks relating to our development and commercialization of additional diagnostic solutions including cell-free DNA, which is a lengthy and complex process that may not be successful. . These factors, together with those that are described in greater detail in the Annual Report on Form 10-K filed by us with the SEC on March 31, 2015, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to publicly update or revise any forward looking statements to reflect events that occur or circumstances that exist after the date on which they were made.